NASDAQ
21.64USD
0.00 (0.00%)
We have scored 10 news catalysts on Avadel Pharmaceuticals plc (AVDL) over the past 12 months. The biggest single-day move next to one of them came Dec 2, 2025, when AVDL closed +0.3%: “Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options | DelveInsight”. Coverage across the window leans positive (average ticker sentiment +0.64). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.1B
P/E
—
EPS
—
Beta
1.31
52W range
6.38-23.57
Day range
21.64–21.64
Open
21.64
Prev close
21.64
Volume
35M
Avg volume
2.4M
Dividend
0.00
IPO
1996-06-07
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Avadel Pharmaceuticals plc — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Avadel Pharmaceuticals plc, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for AVDL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
